(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






1348 Result: medical

Cancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring

April 24th, 2017

* Complete::IO™ provides immune endpoint and immune monitoring of patients allowing informed therapeutic decisions and assessment of potential toxicities of IO therapies in blood cancers and solid tumors * Complete::IO™ can determine pre. Read more

Auris Medical Reports Key Results from Keyzilen(R) AMPACT2 Open-Label Extension Study

April 24th, 2017

* Trial outcomes show positive safety profile of Keyzilen® for chronic intermittent use * Exploratory efficacy results support therapeutic concept of early tinnitus treatment Zug, Switzerland / CRWE PRESS RELEASE / April 24, 2017 - Auris Medi. Read more

CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial

April 20th, 2017

Bedminster, NJ / CRWE PRESS RELEASE / April 20, 2017 - CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,. Read more

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

April 18th, 2017

- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more

CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

April 16th, 2017

ROCKVILLE, Md. / CRWE PRESS RELEASE / April 14, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, reported today that along with the inv. Read more

Abbott and Alere Amend Terms of Merger Agreement

April 16th, 2017

ABBOTT PARK, Ill. and WALTHAM, Mass. / CRWE PRESS RELEASE / April 14, 2017 - Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today that the companies have agreed to amend the existing terms of their agreement for Abbott's acquisition of A. Read more

AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues

April 13th, 2017

CAMBRIDGE, Mass. / CRWE PRESS RELEASE / April 13, 2017 - AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Is. Read more

Alere Achieves FDA Clearance for Alere(TM) Reader Platform and Alere BinaxNOW(R) Influenza A & B Card 2

April 11th, 2017

WALTHAM, Mass. / CRWE PRESS RELEASE / April 11, 2017 - Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that its Alere™ Reader, a diagnostic analyzer that can be used in both point-of-care and laboratory settings, h. Read more

Takeda Enters into Strategic Collaboration with NuBiyota for Microbiome Therapeutics

April 11th, 2017

Osaka, Japan / CRWE PRESS RELEASE / April 11, 2017 - Takeda Pharmaceutical Company Limited (TSE:4502) today announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterolog. Read more

Cemtrex Receives Multi-million Dollar Order From New Customer

April 10th, 2017

Farmingdale, NY / CRWE PRESS RELEASE / April 10, 2017 — Cemtrex Inc. (Nasdaq: CETX, CETXW, CETXP), a world leading industrial and manufacturing solutions company, announced today that it received a multi-million dollar order from a new cus. Read more

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancer

April 02nd, 2017

Caligor Opco LLC to Provide Regulatory and Logistical Management LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the. Read more

miRagen Therapeutics Provides Corporate Update

March 31st, 2017

BOULDER, CO / CRWE PRESS RELEASE / March 31, 2017 - miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today reported recent clinical and fina. Read more

Corindus Announces First Robotic-Assisted PCI Procedures Performed in Asia Using CorPath(R) GRX System

March 31st, 2017

Live Case Transmitted from Fu Wai Hospital to China Interventional Therapeutics Conference in Beijing Waltham, MA / CRWE PRESS RELEASE / March 31, 2017 - Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular . Read more

miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides

March 31st, 2017

BOULDER, CO / CRWE PRESS RELEASE / March 31, 2017 - miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food. Read more

Cellect Announces Successful First Cancer Patient Stem Cell Transplant

March 27th, 2017

Cellect’s technology, ApoGraft™, aims to become a game changer in stem cells transplantations for cancer treatments Company gets green light from DSMB Board for enrolling additional 2 cancer patients for ApoGraft™ transplantation. Read more

Load More Content